Market Place
Sourcing Support
23andMe shutters cancer drug research, lays off 40% of staff
11 Nov 2024 //
FIERCE BIOTECH
23&Me Announces Restructuring to Cut Costs & Streamline Operations
11 Nov 2024 //
GLOBENEWSWIRE
23&Me to Report Q2 FY2025 Financial Results
07 Nov 2024 //
GLOBENEWSWIRE
23andMe Regains Compliance With Nasdaq Listing Requirements
30 Oct 2024 //
GLOBENEWSWIRE
23andMe Appoints Three New Independent Directors to Board
29 Oct 2024 //
GLOBENEWSWIRE
23andMe Helps African Americans Trace Roots To Post-Slavery South
17 Oct 2024 //
GLOBENEWSWIRE
23andMe Announces Completion of 1-for-20 Reverse Stock Split
16 Oct 2024 //
GLOBENEWSWIRE
23andMe Announces 1-for-20 Reverse Stock Split
11 Oct 2024 //
GLOBENEWSWIRE
23andMe Announces Mathew Knowles as New Brand Ambassador
08 Oct 2024 //
GLOBENEWSWIRE
23andMe Launches New Genetic Report On Emotional Eating
25 Sep 2024 //
GLOBENEWSWIRE
23andMe independent directors quit board over unsatisfactory plan from CEO
18 Sep 2024 //
REUTERS
Independent Directors of 23andMe Resign from Board
17 Sep 2024 //
GLOBENEWSWIRE
23andMe Reports Positive Results For ULBP6-Targeting Antibody 23ME-01473
16 Sep 2024 //
GLOBENEWSWIRE
23andMe Announces Phase 2 Results For 23ME-00610 In Cancer Cohorts
15 Sep 2024 //
GLOBENEWSWIRE
23andMe settles data breach lawsuit for $30 million
14 Sep 2024 //
REUTERS
Large Study Reveals Sickle Cell Trait And Blood Clot Link
12 Sep 2024 //
GLOBENEWSWIRE
23andMe CEO Open To Third-Party Takeover Proposals, Filing Shows
11 Sep 2024 //
REUTERS
23andMe to Present Immuno-Oncology Updates at ESMO Congress 2024
03 Sep 2024 //
GLOBENEWSWIRE
Lemonaid Health Offers GLP-1 Medication In Weight Loss Program
28 Aug 2024 //
GLOBENEWSWIRE
23andMe Reports First Quarter Fiscal 2025 Financial Results
08 Aug 2024 //
GLOBENEWSWIRE
23andMe Special Committee responds to CEO’s take-private proposal
02 Aug 2024 //
GLOBENEWSWIRE
Genetic testing firm 23andMe rejects CEO`s take-private offer
02 Aug 2024 //
REUTERS
23andMe Announces CEO’s Take-Private Proposal
01 Aug 2024 //
GLOBENEWSWIRE
Lung Cancer Advocacy Groups And 23andMe Launch Genetics Study
25 Jul 2024 //
GLOBENEWSWIRE
23andMe to Report Q1 FY2025 Financial Results
25 Jul 2024 //
GLOBENEWSWIRE
23andMe And Nightingale Health Announce Collaboration For Blood Biomarker Panel
28 Jun 2024 //
GLOBENEWSWIRE
23andMe Launches New Genetic Report on Bipolar Disorder
05 Jun 2024 //
GLOBENEWSWIRE
23andMe, CCA: Advancing Colorectal Cancer Research In Black Community
04 Jun 2024 //
GLOBENEWSWIRE
23andMe`s 23ME-00610 CD200R1 Positive Phase 2 Results At ASCO
03 Jun 2024 //
GLOBENEWSWIRE
Largest LRRK2 Study Reveals Health, Ancestry, History Insights
29 May 2024 //
GLOBENEWSWIRE
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
23 May 2024 //
GLOBENEWSWIRE
23andMe to Report Q4 and Full Year FY2024 Financial Results
09 May 2024 //
GLOBENEWSWIRE
23andMe to Present 23ME-00610 Efficacy & Biomarker Data at ASCO 2024
24 Apr 2024 //
GLOBENEWSWIRE
23andMe announces CEO`s intention to pursue a potential take-private
18 Apr 2024 //
GLOBENEWSWIRE
23andMe`s CEO files plan to take company private
18 Apr 2024 //
ENDPTS
23andMe to Present Data at AACR Annual Meeting 2024
05 Apr 2024 //
GLOBENEWSWIRE
23andMe Initiates Ph1 Trial for its Dual MOA, 23ME-01473, Targeting ULBP6
20 Mar 2024 //
GLOBENEWSWIRE
23&Me Launches New Feature Connecting Customers to Historical Individuals
19 Mar 2024 //
GLOBENEWSWIRE
23andMe Launches New Genetic Reports on Common Forms of Cancer
06 Mar 2024 //
GLOBENEWSWIRE
23andMe Announces Presentations from Clinical-Stage Immuno-Oncology Programs
05 Mar 2024 //
GLOBENEWSWIRE
23andMe Reports Third Quarter Fiscal 2024 Financial Results
07 Feb 2024 //
GLOBENEWSWIRE
23andMe Announces FDA Clearance of IND Application for 23ME-01473
31 Jan 2024 //
GLOBENEWSWIRE
23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program
30 Jan 2024 //
GLOBENEWSWIRE
23andMe to Report FY2024 Third Quarter Financial Results
24 Jan 2024 //
GLOBENEWSWIRE
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial
19 Dec 2023 //
GLOBENEWSWIRE
23andMe Reports Second Quarter Fiscal 2024 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
23andMe Launches Total Health, its Prevention-Based Health Membership
07 Nov 2023 //
GLOBENEWSWIRE
23andMe Announces Safety Data From the Phase 1/2a Study of 23ME-00610
06 Nov 2023 //
GLOBENEWSWIRE
23andMe Launches Action Plan to Provide Recommendations Based on Genetic Data
31 Oct 2023 //
GLOBENEWSWIRE
23andMe Announces Collaboration Extension with Data Licensing Agreement with GSK
30 Oct 2023 //
GLOBENEWSWIRE
23andMe to Report FY2024 Second Quarter Financial Results
25 Oct 2023 //
GLOBENEWSWIRE
23andMe notifies customers of data breach into its `DNA Relatives` feature
24 Oct 2023 //
REUTERS
23andMe Announces Poster Presentations on 23ME-00610
27 Sep 2023 //
GLOBENEWSWIRE
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
14 Sep 2023 //
GLOBENEWSWIRE
23andMe gets US FDA 510(k) clearance to expand its existing BRCA1/BRCA2 report
04 Sep 2023 //
PHARMABIZ
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
31 Aug 2023 //
GLOBENEWSWIRE
23andMe Reports FY2024 First Quarter Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
23andMe to Report FY2024 First Quarter Financial Results
25 Jul 2023 //
GLOBENEWSWIRE
23andMe Releases New FDA-Cleared Genetic Report on Simvastatin
20 Jul 2023 //
GLOBENEWSWIRE
23andMe Releases New Report Revealing Genetic Likelihood of Panic Attacks
21 Jun 2023 //
GLOBENEWSWIRE
